Your Health, We Care
Another NameMulpleta,LuciRux,芦曲泊帕
IndicationsIt is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who develop the condition prior to undergoing surgery.
Reg No.11 L 1250/24
Inspection NO.2778-24
Lusutrombopag manufactured by Lucius Pharmaceuticals is an oral thrombopoietin receptor agonist with favorable efficacy and safety, providing a convenient treatment option for preoperative platelet management in patients with chronic liver disease.
Overview of the Main Information of Lusutrombopag.
The main active ingredient is lusutrombopag, with a content of 3mg per tablet.
It is indicated for adult patients with chronic liver disease complicated by thrombocytopenia who are scheduled to undergo surgery.
The recommended dose is 3mg orally once daily for 7 consecutive days, and the surgery should be performed within 2-8 days after the last dose.
Pregnant women should use the drug after weighing the benefits and risks; lactating women should suspend breastfeeding during medication; the safety of pediatric use has not been established; and the medication data in elderly patients is limited.
Drug overdose may lead to excessive elevation of platelets and increase the risk of thrombosis. Close monitoring and symptomatic treatment are required.
The drug should be stored in its original packaging at room temperature and kept out of reach of children.
Lusutrombopag is slowly absorbed after oral administration, with a half-life of approximately 27 hours, and is mainly excreted via feces.
FDA，2018.07
